About Mammotome
Mammotome is a Healthcare company based in Cincinnati (United States) founded in 1959, and was acquired by Leica Biosystems in October 2014. Minimally invasive breast biopsy systems are developed for cancer sampling. It operates on a Direct-to-Consumer (D2C) and Professional Services model. Mammotome has raised $14 million across 1 funding round from investors including Leica Biosystems. The company has 169 employees. Mammotome has completed 1 acquisition, including Neoprobe. Mammotome offers products and services including Neoprobe® Gamma Detection System, Pintuition® System, Mammotome Revolve™ EX System, Mammotome® Elite System, and Mammotome® Markers. Its focus areas include Medical Devices and Diagnostic Equipment. Its legal entity is DEVICOR MEDICAL PRODUCTS, INC. Its competitors include PreludeDx, POC Medical Systems and Gamma Medica; 3 of its 3 listed competitors have raised funding.
Company details
Mammotome is dedicated to the development of innovative technologies for breast cancer diagnostics and surgical solutions. The company operates in the healthcare sector, providing best-in-class medical devices for breast biopsy and local surgical treatments. Solutions offered include gamma detection systems, surgical marker navigation, and vacuum-assisted biopsy devices. Mammotome supports clinicians with efficient tools while prioritizing patient care in every breast cancer journey. The global team collaborates to improve outcomes through advanced clinical capabilities across multiple countries.
- Headquarters Cincinnati, United States
- Employees 169
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website mammotome.com
- Social LinkedIn X Facebook
- Acquired by Leica Biosystems (Oct 2014)
- Legal Name Devicor Medical Products, Inc.
- Total Equity Funding$14M (USD)
in 1 rounds
- Latest Funding Round$14M (USD), Series A
Jul 2010
- Investors
- Employee Count169
- Investments & Acquisitions
- Acquired byLeica Biosystems
(Oct 2014)
Products & Services of Mammotome
Mammotome offers a comprehensive portfolio of products and services, including Neoprobe® Gamma Detection System, Pintuition® System, Mammotome Revolve™ EX System, Mammotome® Elite System, and Mammotome® Markers.
System designed for accurate gamma detection in surgery.
Navigation system developed for intuitive surgical marker guidance.
Device created for minimally invasive breast lesion excision.
Biopsy device engineered for quality tissue sampling ease.
Markers provided for comprehensive breast biopsy site identification.
Funding Insights of Mammotome
Mammotome has successfully raised a total of $14M through 1 strategic funding round. The most recent funding activity was a Series A round of $14 million completed in July 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14M
- Total Rounds 1
- Last Round Series A — $14M
- First Round $14M
(Jul 2010)
All 1 funding rounds of Mammotome with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2010 | $14M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Mammotome
Mammotome has secured backing from 1 investor. Prominent investors backing the company include Leica Biosystems.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provides tools for anatomic pathology, histology, and digital cancer diagnostics worldwide. | 1989 | leicabiosystems.com | Nussloch, Germany |
Investor details for Mammotome
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Mammotome
76 people are tracked at Mammotome (14 in leadership, 62 in team); the tracked headcount is 169.
| Name | Role | Group |
|---|---|---|
Erica Bednar | Marketing Director | Leadership |
Joseph Vandehei | Director, Sales Operations And Global Service | Leadership |
Uwe Soeder | Chief Financial Officer | Leadership |
Antonio Miller | Senior Director, Human Resources | Leadership |
Jack Cummings | Director, Quality & Regulatory Affairs | Leadership |
Ami Ackerman | Director, Human Resources | Leadership |
Lauren Flakne | Director Of Innovation & Engineering | Leadership |
Arjun Sridhar | Director, Global Product Management | Leadership |
Jack Randall | Director Of Engineering | Leadership |
Andrew Small | Director Of Project Management | Leadership |
Jeff McClure | Director, Technical Engineering Services | Leadership |
Raffaella Marcandoro | Director Of EMEA Marketing | Leadership |
Katie Osborne | Director, Global Product Management, Biopsy Markers & Localization | Leadership |
Karen Isaacs | Vice President Of R&d & Engineering | Leadership |
Shelby Lewis | Associate Sales Representative | Team |
Ally Baumgart | Senior Systems Engineer | Team |
Nathan Busick | Sr Manager - Capital Manufacturing Engineering And Supplier Management Engineering | Team |
Ritesh Varma | Senior Electrical Engineer | Team |
Jina Rebellino | Creative Services Manager | Team |
Michael Schmidt | Senior Global Sales Support Manager | Team |
56 more people are available in the full profile.
Complete people profiles for Mammotome
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Mammotome
Mammotome has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Neoprobe.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Gamma detection devices and radiopharmaceuticals for cancer are provided. | neoprobe.com | Cincinnati, United States | 1996 | May 2011 | $30M |
Complete acquisition details for Mammotome
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Mammotome
4 dated milestones of Mammotome across 55 years, from founding to its latest funding, stage changes and deals.
- Founded Mammotome is founded.
- Funding First funding round of $14.0M.
- Acquisition Acquires Neoprobe.
- Exit Acquired by Leica Biosystems.
Competitors of Mammotome
Mammotome has 3 listed competitors in our database, 3 of them funded. They include PreludeDx, POC Medical Systems and Gamma Medica.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| preludedx.com | 2009 | Laguna Hills, United States | $46.65M | 33 | Risk assessment tests for early-stage breast cancer are provided. | |
| pocmedicalsystems.com | 2013 | Livermore, United States | $22.1M | 58 | Develops rapid tools for breast cancer detection and disease screening worldwide. | |
| gammamedica.com | 2013 | Salem, United States | $27.5M | Company offering molecular breast imaging for cancer diagnosis |
Detailed competitors of Mammotome
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Mammotome
The website of Mammotome (mammotome.com) receives about 7.1K visits a month.
- Monthly visits7.1K
▼ 8.9% vs previous month
Websites whose visitors overlap most with Mammotome. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
temeculaimaging.com | temeculaimaging.com | 100% | – | ||
inhealthgroup.com | inhealthgroup.com | 98% | #489,756 | – | |
sitron-hammel.com | sitron-hammel.com | 98% | – | ||
| koppdevelopment.com | 69% | #9,629,439 | View details | ||
| fmig.com.au | 63% | 12.7K | #1,831,708 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 10 similar websites and full traffic analytics for Mammotome
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Mammotome (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mammotome
Complete news archive for Mammotome
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mammotome
Mammotome was founded in 1959 and raised its 1st funding round 51 years after it was founded.
Mammotome is headquartered in Cincinnati, United States. It is registered at Cincinnati, Ohio, United States.
Mammotome is a funded company, having raised a total of $14M across 1 funding round to date. The company's 1st funding round was a Series A of $14M, raised on Jul 2010.
Mammotome has 169 employees.
Mammotome is dedicated to the development of innovative technologies for breast cancer diagnostics and surgical solutions. The company operates in the healthcare sector, providing best-in-class medical devices for breast biopsy and local surgical treatments. Solutions offered include gamma detection systems, surgical marker navigation, and vacuum-assisted biopsy devices. Mammotome supports clinicians with efficient tools while prioritizing patient care in every breast cancer journey. The global team collaborates to improve outcomes through advanced clinical capabilities across multiple countries.
Mammotome's top competitors include PreludeDx, Gamma Medica and POC Medical Systems.
Mammotome offers Neoprobe® Gamma Detection System, Pintuition® System, Mammotome Revolve™ EX System, Mammotome® Elite System, and Mammotome® Markers.
Mammotome has made 1 acquisition, including Neoprobe.
Mammotome has 1 investor. Key investors include Leica Biosystems.
Mammotome operates through Devicor Medical Products, Inc..
Yes. Mammotome was acquired by Leica Biosystems in October 2014.